大B细胞淋巴瘤中CD19靶向CAR-T细胞治疗的比较真实世界结局
这项回顾性多中心队列研究纳入2016年4月至2024年7月接受CD19靶向CAR-T治疗的624例复发/难治性大B细胞淋巴瘤患者(axi-cel 344例、tisa-cel 142例、liso-cel 138例),中位随访20.9个月。多因素校正后,tisa-cel相比axi-cel与更差的PFS和OS相关;liso-cel与axi-cel间无显著生存差异。axi-cel的细胞因子释放综合征、免疫效应细胞相关神经毒性综合征、免疫效应细胞相关血液毒性及发热性中性粒细胞减少发生率显著更高。
要点
- 中位随访20.9个月,2年PFS率:axi-cel 46%、tisa-cel 30%、liso-cel 45%。
- 2年OS率:axi-cel 63%、tisa-cel 45%、liso-cel 58%。
- 多因素校正后tisa-cel相比axi-cel与更差PFS和OS相关,liso-cel与axi-cel无显著生存差异。
核心结论
- 多因素校正后,tisa-cel相比axi-cel与更差的PFS和OS相关;liso-cel与axi-cel之间未发现显著生存差异。
研究设计与样本
- 回顾性多中心队列研究,纳入2016年4月至2024年7月接受CD19靶向CAR-T细胞治疗的624例复发/难治性大B细胞淋巴瘤患者,其中axi-cel 344例、tisa-cel 142例、liso-cel 138例。
主要发现
- 中位随访20.9个月,估计2年PFS率分别为axi-cel 46%、tisa-cel 30%、liso-cel 45%,2年OS率分别为axi-cel 63%、tisa-cel 45%、liso-cel 58%。
- 多因素分析校正潜在混杂因素后,tisa-cel相比axi-cel与更差的PFS和OS相关;liso-cel与axi-cel之间未发现显著生存差异。
- 倾向评分分析及二线对比三线或更后线治疗的亚组分析得到相似结果。
- 相比axi-cel,100天客观缓解率liso-cel更高、tisa-cel更低;axi-cel的细胞因子释放综合征、免疫效应细胞相关神经毒性综合征、免疫效应细胞相关血液毒性及发热性中性粒细胞减少发生率显著更高;感染累积发生率或非复发死亡率未见显著差异。
- axi-cel的静脉到静脉时间更快(axi-cel 35天、tisa-cel 43天、liso-cel 41天),不合格产品更少(axi-cel 2%、tisa-cel 4%、liso-cel 11%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although 3 commercial CD19-targeted chimeric antigen receptor (CAR) T-cell therapies are available for large B-cell lymphomas (LBCLs), no randomized clinical trials have compared their efficacy and safety. In this retrospective multicenter cohort study, we evaluated real-world clinical outcomes of patients with relapsed/refractory LBCL treated with axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), or lisocabtagene maraleucel (liso-cel). Between April 2016 and July 2024, 624 patients received CD19-targeted CAR T-cell therapies (344 axi-cel, 142 tisa-cel, and 138 liso-cel). At a median follow-up of 20.9 months, the respective estimated 2-year progression-free survival (PFS) and overall survival (OS) rates were 46% and 63% for axi-cel, 30% and 45% for tisa-cel, and 45% and 58% for liso-cel. After adjusting for potential confounders in multivariate analyses, tisa-cel was associated with inferior PFS and OS compared to axi-cel. No significant survival differences were found between liso-cel and axi-cel. Propensity score and subanalyses of patients treated in the second-line vs third-line or later settings yielded similar outcomes. Compared to axi-cel, the objective response rate at 100 days was higher for liso-cel and lower for tisa-cel. Rates of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and immune effector cell-associated hematotoxicity, and febrile neutropenia were significantly higher with axi-cel. However, no significant differences in the cumulative incidence of infections or nonrelapse mortality were found. Axi-cel was associated with faster vein-to-vein time (axi-cel, 35 days; tisa-cel, 43 days; liso-cel, 41 days) and fewer out-of-specification products (axi-cel, 2%; tisa-cel, 4%; liso-cel, 11%). These results provide insights into potential differential outcomes depending on product selection.
引用
- Deschênes-Simard X, Bromberg M, Devlin SM, et al. Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma. Blood Adv. 2025. PMID: 40815804. doi:10.1182/bloodadvances.2025016778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。